| Ytd | 29.83% | |
| 1y | 248.28% |
| Open | 41.40 | Prev Close | 41.67 | Low | 39.26 | High | 41.99 | Mkt Cap | 1.88B |
| Vol | 296.94K | Avg Vol | 358.11K | EPS | -2.60 | P/E | N/A | Forward P/E | -8.96 |
| Beta | 0.98 | Short Ratio | 7.43 | Inst. Own | 109.54% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 37.22 | 200-d Avg | 30.63 | 1yr Est | 56.64 |
RAPP News
Leerink Partners analyst Marc Goodman initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) wi
BTIG analyst Kambiz Yazdi maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the
Truist Securities analyst Danielle Brill assumes Rapport Therapeutics (NASDAQ:RAPP) with a Buy ra
BTIG analyst Kambiz Yazdi reiterates Rapport Therapeutics (NASDAQ:RAPP) with a Buy and maintains
Rapport Therapeutics (NASDAQ:RAPP) reported quarterly losses of $(0.42) per share which beat the ana
BTIG analyst Kambiz Yazdi maintains Rapport Therapeutics (NASDAQ:RAPP) with a Buy and raises the
Wells Fargo analyst Benjamin Burnett maintains Rapport Therapeutics (NASDAQ:RAPP) with a Overweig
Common StockPreferred StockDebt SecuritiesWarrantsUnitsWe may from time to time issue, in one or mor
Rapport Therapeutics (NASDAQ:RAPP) reported quarterly losses of $(0.72) per share which missed the a
Xenon Pharmaceuticals shares surge after Phase 3 data show strong seizure reduction for azetukalner,
Wells Fargo analyst Benjamin Burnett initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) wit
CLINICAL AND PIPELINE UPDATESRapport is prioritizing programs it believes have the greatest potentia
HC Wainwright & Co. analyst Douglas Tsao maintains Rapport Therapeutics (NASDAQ:RAPP) with a
Post-hoc analysis of RAP-219 Phase 2a data showed early onset of action and consistency of median re
BTIG analyst Kambiz Yazdi initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Buy rat
Citizens analyst Jason N. Butler maintains Rapport Therapeutics (NASDAQ:RAPP) with a Market Outpe
Rapport Therapeutics (NASDAQ:RAPP) reported quarterly losses of $(0.71) per share which beat the ana
Truist Securities analyst Joon Lee initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with
Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-st
Rapport Therapeutics' RAP-219 cut seizures significantly in a Phase 2a trial, with strong result
HC Wainwright & Co. analyst Douglas Tsao maintains Rapport Therapeutics (NASDAQ:RAPP) with a
RAPP: 176% | Rapport Therapeutics' Phase 2a Trial Of RAP-219 In Drug-Resistant Focal Onset Seizu
Trial met primary long episode endpoints with high statistical significance, and RAP-219 was general
Rapport Therapeutics, Inc.
Rapport Therapeutics (NASDAQ:RAPP) reported quarterly losses of $(0.75) per share which beat the ana
HC Wainwright & Co. analyst Douglas Tsao initiates coverage on Rapport Therapeutics (NASDAQ:R
